The salmeterol multicenter asthma research trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

Chest

Volumn 129, Issue 1, 2006, Pages 15-26

  Nelson, Harold S ^a   Weiss, Scott T ^b   Bleecker, Eugene K ^c   Yancey, Steven W ^d   Dorinsky, Paul M ^d  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Long acting 2 agonist; Salmeterol

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; MONTELUKAST; ORCIPRENALINE; PLACEBO; PREDNISONE; SALBUTAMOL; SALMETEROL XINAFOATE; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ASTHMA; CAUCASIAN; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME;

EID: 33144476873     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.1.15     Document Type: Conference Paper

References (20)

1. Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for Asthma-United States, 1980-1999. MMWR Morb Mortal Wkly Rep 2002; 51(SS-1):1-14
2. Strunk RC, Ford JG, Taggart V. Reducing disparities in asthma care: priorities for research; National Heart, Lung, and Blood Institute workshop report. J Allergy Clin Immunol 2002; 109:229-237
3. Speizer FE, Doll R, Heaf P, et al. Investigation into use of drugs preceding death from asthma. BMJ 1968; 1:339-343
4. Stolley PD. Asthma mortality: why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972; 105:883-890
5. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: a case-control study. Lancet 1989; 917-922
6. Pearce NE, Grainger J, Atkinson M. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-1981. Thorax 1990; 170-175
7. Grainger J, Woodman K, Pearce NE, et al. Prescribed fenoterol and death from asthma in New Zealand 1981-7: a further case-control study. Thorax 1991; 46:105-111
8. Mann RD, Kubota K, Pearce G, et al. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996; 49:247-250
9. Lanes SF, Lanza L, Wentworth CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Grit Care Med 1998; 158:857-861
10. Meier CR, Jick H. Drug use and pulmonary death rates in increasing symptomatic asthma patients in the UK. Thorax 1997; 52:612-617
11. Williams C, Grassland L, Finnerty J, et al. A case-control study of salmeterol and near-fatal attacks of asthma. Thorax 1998; 53:7-13.
12. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-1037
13. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci 2000; 97:10483-10488
14. Taylor DR, Kennedy MA. β-Adrenergic receptor polymorphisms and drug responses in asthma. Pharmacogenomics 2002; 3:173-184
15. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343:332-336
16. Donahue G, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277:887-891
17. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320:1368-1373
18. Martin RM, Shakir S. Age- and gender-specific asthma death rates in patients taking long-acting β-2 agonists. Drug Safety 2001; 24:475-481
19. Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005; 330:117-124
20. Adams RJ, Weiss ST, Fuhlbrigge A. How and by whom care is delivered influences anti-inflammatory use in asthma: results of a national population survey. J Allergy Clin Immunol 2003; 112:445-450